期刊
NATURE GENETICS
卷 48, 期 10, 页码 1131-1141出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ng.3659
关键词
-
资金
- Cancer Research UK [RG66287, RG81771, RG84119, C14303/A17197]
- Addenbrooke's Hospital
- UCL
- NIHR Professorship [RG67258]
- Medical Research Council [RG84369]
- Experimental Cancer Medicine Centre [RG62923]
- University of Cambridge
- Hutchison Whampoa Limited
- Department of Health's NIHR Biomedical Research Centres
- CRUK UCL Early Cancer Medicine Centre
- Cancer Research UK [22310, 15874, 19556] Funding Source: researchfish
- Cancer Research UK
- Versus Arthritis [20406] Funding Source: researchfish
- Medical Research Council [G1002565] Funding Source: researchfish
- MRC [G1002565] Funding Source: UKRI
Esophageal adenocarcinoma (EAC) has a poor outcome, and targeted therapy trials have thus far been disappointing owing to a lack of robust stratification methods. Whole-genome sequencing (WGS) analysis of 129 cases demonstrated that this is a heterogeneous cancer dominated by copy number alterations with frequent large-scale rearrangements. Co-amplification of receptor tyrosine kinases (RTKs) and/or downstream mitogenic activation is almost ubiquitous; thus tailored combination RTK inhibitor (RTKi) therapy might be required, as we demonstrate in vitro. However, mutational signatures showed three distinct molecular subtypes with potential therapeutic relevance, which we verified in an independent cohort (n = 87): (i) enrichment for BRCA signature with prevalent defects in the homologous recombination pathway; (ii) dominant T>G mutational pattern associated with a high mutational load and neoantigen burden; and (iii) C>A/T mutational pattern with evidence of an aging imprint. These subtypes could be ascertained using a clinically applicable sequencing strategy (low coverage) as a basis for therapy selection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据